Article Figures & Data
Figures
- FIGURE 1.
Patient with nonfunctioning endocrine tumor. 111In-pentetreotide scintigraphy shows celiac tumors with liver metastases.
- FIGURE 2.
Same patient as in Figure 1. Celiac tumoral and liver metastases are not shown by 99mTc-P829 scintigraphy.
- FIGURE 3.
Patient with Zollinger-Ellison syndrome. 111In-pentetreotide scintigraphy shows multiple celiac tumors with liver and lung metastases.
- FIGURE 4.
Same patient as in Figure 3. 99mTc-P829 scintigraphy shows lung metastases (smaller than those shown by 111In-pentetreotide scintigraphy). Celiac tumors are not detected. Liver metastases are not clearly seen.
Tables
Tumor site 111In-Pentetreotide 99mTc-P829 Head and neck 6 5 Lung and mediastinum 10 11 Liver 129 34 Celiac area: upper abdomen 41 23 Lower abdomen 7 2 Bone 10 2 Total 203 77
In this issue
Jump to section
Related Articles
Cited By...
- Radiopeptide Imaging and Therapy in Europe
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience
- Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
- Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
- Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
- An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors